Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 17, 2026Journal of Antimicrobial ChemotherapyOpen Access

‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

ACArturo CicculloSan Salvatore HospitalGBGianmaria BaldinAgostino Gemelli University PolyclinicACAdriana CervoUniversity of Modena and Reggio Emilia

Discussion

Loading...

Member takes

Implication

Randomized trial evaluates virological suppression in a large cohort using DTG+3TC, suggesting sustained effectiveness and tolerability.

Key Points

  • The study aims to assess the long-term effectiveness, tolerability, and metabolic safety of DTG+3TC as a switch regimen in people with HIV.
  • Retrospective observational analysis of 2535 participants from the ODOACRE cohort across eight Italian centers
  • Inclusion criteria: age ≥18, HIV-RNA <50 copies/mL for ≥6 months, HBsAg negative
  • Primary outcomes: virological failure and treatment discontinuation assessed using Kaplan-Meier and Cox regression models.
  • 99.5% of participants maintained virological suppression at 48 weeks; 90.4% at 480 weeks
  • 362 treatment discontinuations observed (3.72 per 100 patient years of follow-up)
  • Multivariate analysis identified certain predictors for virological failure, with longer prior virological suppression being protective.

Cite This Study

Ciccullo et al. (2026) studied this question.

synapsesocial.com/papers/6a095c147880e6d24efe2230https://doi.org/10.1093/jac/dkag172
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial2022 · 177 citations
  2. 2HBcAb Positivity as a Risk Factor for Missing HIV RNA Undetectability after the 3TC+DTG Switch2024 · 7 citations
  3. 3Insulin Resistance in HIV-Patients: Causes and Consequences2018 · 83 citations
  4. 4Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials2019 · 218 citations
  5. 5‘With age comes wisdom’: effectiveness and tolerability of dolutegravir + lamivudine in virologically-suppressed people with HIV2025 · 1 citations